Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.
Copenhagen, Denmark-based Genmab A/S raised $506 million with an initial public offering (IPO), with the company trading on the Nasdaq under the ticker symbol GMAB.
The IASLC, Guardant Health, the Global Lung Cancer Coalition and AstraZeneca announced the Lung Ambition Alliance, a new partnership to eliminate lung cancer as a cause of death.
Century Therapeutics, a startup founded by Versant Ventures, launched with $250 million in hand and a focus on developing induced pluripotent stem cell-based therapies for the treatment of hematologic and solid malignancies.
Denmark-based Genmab A/S and Janssen Biotech will collaborate on a successor to the multiple myeloma drug Darzalex with the development of a next-generation CD38 antibody product for the treatment of multiple myeloma and diffuse large B-cell lymphoma.
W2O Announces Investment from New Mountain Capital; Partnership Focused on Making the World a Healthier Place through Marketing Communications
W2O announced a partnership with New Mountain Capital to accelerate continued growth and scale of the company to meet the evolving needs of its clients to most effectively and efficiently communicate with and influence their key stakeholders in an increasingly digital and mobile world.
Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.
Eisai Co. Ltd. initiated Phase 3 clinical trials of the Alzheimer’s treatment BAN2401 one day after the Japanese drugmaker and U.S. partner Biogen Inc. scrapped studies for the Alzheimer’s drug aducanumab.
Universal Medica Group and EVERSANA announce global medical information and pharmacovigiliance service partnership
Universal Medica Group and EVERSANA announced a definitive partnership, increasing their global footprint and enhancing their expertise in the life sciences and healthcare industry.